サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424030

フィブラート系薬剤市場、シェア、規模、動向、産業分析レポート：薬剤別、製品タイプ別、形態別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Fibrate Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug (Clofibrate, Gemfibrozil, Fenofibrate, Others); By Product Type; By Form; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
フィブラート系薬剤市場、シェア、規模、動向、産業分析レポート：薬剤別、製品タイプ別、形態別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のフィブラート系薬剤市場規模は2032年までに50億4,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

運動不足、ライフスタイルの変化、タバコやアルコールの消費量の増加などの要因が、成人人口のコレステロール異常のリスクを高めています。例えば、世界保健機関（WHO）によると、2023年7月、タバコにより毎年800万人以上が死亡しています。これは心臓病のリスクを高める。さらに、冠動脈疾患、心臓発作、末梢動脈疾患などの心血管疾患を患う患者の増加が、フィブラート系薬剤の需要を牽引しています。

トリグリセリド、低比重リポ蛋白（LDL）コレステロール、高比重リポ蛋白（HDL）コレステロールなどの脂質の不均衡につながる脂質異常症は、予測期間中にフィブラート系薬剤の必要性を高めると思われます。例えば、2022年9月には、インド人の10人に6人がコレステロール値に異常があります。このようなコレステロール値の異常は、予測期間中にフィブラート系薬剤の需要を増加させると思われます。

糖尿病と体内のLDL、HDL、トリグリセリドなどの脂質量の変化との関連性が市場の成長に寄与しています。したがって、糖尿病患者の増加に伴い、フィブラート系薬剤の需要も予測期間中に増大します。例えば、国際糖尿病連合（IDF）によると、インドでは2021年に糖尿病を患う成人は7億7,420万人で、有病率は8.3%です。さらに、コレステロール異常に対する新しく効果的な治療法の開発と上市に市場関係者が常に注力していることが、今後数年間におけるフィブラート系薬剤市場の成長を促進することになるでしょう。

フィブラート系薬剤市場レポートハイライト

フェノフィブラート系薬剤は、トリグリセリド値およびLDLコレステロール値を低下させる高い有効性により、大きな成長が見込まれます。

各社が保有する強力な特許ポートフォリオにより、ブランドセグメントが市場を独占しています。

錠剤セグメントは、保存期間が長く、有効成分の高用量への対応が可能なことから、最大の市場シェアを占めています。

病院・小売薬局セグメントは、入院患者数の増加により最大の市場シェアを占めました。

北米は、冠動脈性心疾患の負担が大きく、コレステロール異常の発生率が上昇していることから、市場を独占しています。

市場プレイヤーには、Viatris Inc.、Aurobindo Pharma、Lupin Pharmaceuticals, Inc.、AbbVie Inc.、Sun Pharmaceutical Industries Ltd.、ANI Pharmaceuticals, Inc.

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のフィブラート系薬剤市場に関する洞察

  • フィブラート系薬剤- 業界スナップショット
  • フィブラート系薬剤の市場力学
    • 促進要因と機会
      • 低密度リポタンパク質（LDL）レベルの増加に伴う高いリスクが市場の成長を大きく推進します
      • 世界中で糖尿病の有病率が増加しているため、フィブラート系薬剤の需要が高まると予想されています
    • 抑制要因と課題
      • 代替治療選択肢の利用可能性により、フィブラート系薬剤の需要が制限されている
  • PESTLE分析
  • フィブラート系薬剤業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のフィブラート系薬剤市場、薬剤別

  • 主な調査結果
  • イントロダクション
  • クロフィブラート
  • ゲムフィブロジル
  • フェノフィブラート
  • その他

第6章 世界のフィブラート系薬剤市場、製品タイプ別

  • 主な調査結果
  • イントロダクション
  • ブランド
  • ジェネリック

第7章 世界のフィブラート系薬剤市場、形態別

  • 主な調査結果
  • イントロダクション
  • カプセル
  • タブレット

第8章 世界のフィブラート系薬剤市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院および小売薬局
  • オンライン薬局

第9章 世界のフィブラート系薬剤市場、地域別

  • 主な調査結果
  • イントロダクション
    • フィブラート系薬剤の市場評価、地域別、2019年～2032年
  • フィブラート系薬剤市場 - 北米
    • 北米：フィブラート系薬剤市場、薬剤別、2019年～2032年
    • 北米：フィブラート系薬剤市場、流通チャネル別、2019年～2032年
    • 北米：フィブラート系薬剤市場、製品タイプ別、2019年～2032年
    • 北米：フィブラート系薬剤市場、形態別、2019年～2032年
    • フィブラート系薬剤市場 - 米国
    • フィブラート系薬剤市場 - カナダ
  • フィブラート系薬剤市場 - 欧州
    • 欧州：フィブラート系薬剤市場、薬剤別、2019年～2032年
    • 欧州：フィブラート系薬剤市場、流通チャネル別、2019年～2032年
    • 欧州：フィブラート系薬剤市場、製品タイプ別、2019年～2032年
    • 欧州：フィブラート系薬剤市場、形態別、2019～2032年
    • フィブラート系薬剤市場 - 英国
    • フィブラート系薬剤市場 - フランス
    • フィブラート系薬剤市場 - ドイツ
    • フィブラート系薬剤市場 - イタリア
    • フィブラート系薬剤市場 - スペイン
    • フィブラート系薬剤市場 - オランダ
    • フィブラート系薬剤市場 - ロシア
  • フィブラート系薬剤市場 - アジア太平洋
    • アジア太平洋：フィブラート系薬剤市場、薬剤別、2019～2032年
    • アジア太平洋：フィブラート系薬剤市場、流通チャネル別、2019年～2032年
    • アジア太平洋：フィブラート系薬剤市場、製品タイプ別、2019～2032年
    • アジア太平洋：フィブラート系薬剤市場、形態別、2019～2032年
    • フィブラート系薬剤市場 - 中国
    • フィブラート系薬剤市場 - インド
    • フィブラート系薬剤市場 - 日本
    • フィブラート系薬剤市場 - マレーシア
    • フィブラート系薬剤市場 - インドネシア
    • フィブラート系薬剤市場 - 韓国
  • フィブラート系薬剤市場 - 中東・アフリカ
    • 中東・アフリカ：フィブラート系薬剤市場、薬剤別、2019年～2032年
    • 中東・アフリカ：フィブラート系薬剤市場、流通チャネル別、2019年～2032年
    • 中東・アフリカ：フィブラート系薬剤市場、製品タイプ別、2019～2032年
    • 中東・アフリカ：フィブラート系薬剤市場、形態別、2019年～2032年
    • フィブラート系薬剤市場 - サウジアラビア
    • フィブラート系薬剤市場 - 南アフリカ
    • フィブラート系薬剤市場 - イスラエル
    • フィブラート系薬剤市場 - アラブ首長国連邦
  • フィブラート系薬剤市場 - ラテンアメリカ
    • ラテンアメリカ：フィブラート系薬剤市場、薬剤別、2019年～2032年
    • ラテンアメリカ：フィブラート系薬剤市場、流通チャネル別、2019年～2032年
    • ラテンアメリカ：フィブラート系薬剤市場、製品タイプ別、2019年～2032年
    • ラテンアメリカ：フィブラート系薬剤市場、形態別、2019年～2032年
    • フィブラート系薬剤市場 - メキシコ
    • フィブラート系薬剤市場 - ブラジル
    • フィブラート系薬剤市場 - アルゼンチン

第10章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • AbbVie Inc.
  • Ajanta Pharma Inc
  • ANI Pharmaceuticals, Inc
  • Aurobindo Pharma
  • Cipla
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group
図表

List of Tables

  • Table 1 Global Fibrate Drugs Market, by Drug, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Fibrate Drugs Market, by Product Type, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Fibrate Drugs Market, by Form, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Fibrate Drugs Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Fibrate Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 7 North America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 8 North America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 9 North America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 11 U.S.: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 12 U.S.: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 13 U.S.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 15 Canada: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 16 Canada: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 17 Canada: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 19 Europe: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 20 Europe: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 21 Europe: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 23 Germany: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 25 Germany: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 27 France: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 28 France: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 29 France: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 31 UK: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 32 UK: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 33 UK: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 35 Italy: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 36 Italy: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 37 Italy: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 43 Spain: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 44 Spain: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 45 Spain: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 47 Russia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 48 Russia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 49 Russia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 55 China: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 56 China: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 57 China: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 59 Japan: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 60 Japan: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 61 Japan: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 63 India: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 64 India: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 65 India: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 75 South Korea: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 76 South Korea: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 77 South Korea: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 79 Latin America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 80 Latin America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 81 Latin America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 83 Brazil: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 84 Brazil: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 85 Brazil: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 87 Mexico: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 88 Mexico: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 89 Mexico: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 91 Argentina: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 92 Argentina: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 93 Argentina: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 99 UAE: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 100 UAE: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 101 UAE: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 107 South Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 108 South Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 109 South Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • Table 111 Israel: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • Table 112 Israel: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • Table 113 Israel: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Fibrate Drugs Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug
  • Figure 7. Global Fibrate Drugs Market, by Drug, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Fibrate Drugs Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Product Type
  • Figure 11. Global Fibrate Drugs Market, by Product Type, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Form
  • Figure 13. Global Fibrate Drugs Market, by Form, 2021 & 2030 (USD Billion)
目次
Product Code: PM4332

The global fibrate drugs market size is expected to reach USD 5.04 billion by 2032, according to a new study by Polaris Market Research. The report "Fibrate Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug (Clofibrate, Gemfibrozil, Fenofibrate, Others); By Product Type; By Form; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors such as lack of physical exercise, lifestyle changes, and rising consumption of tobacco & alcohol are increasing the risks of cholesterol abnormalities among the adult population. For instance, according to the World Health Organization (WHO), in July 2023, tobacco kills more than 8 million people each year. This increases the risk of heart disease. Moreover, an increasing number of patients suffering from cardiovascular diseases such as coronary artery diseases, heart attacks, and peripheral artery diseases is driving the demand for fibrate drugs.

Dyslipidemia leading to the imbalance of lipids such as triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol will increase the need for fibrate drugs over the forecast period. For instance, in September 2022, 6 in 10 Indians have abnormal levels of cholesterol. Such abnormalities associated with the levels of cholesterol will increase the demand for fibrate drugs over the forecast period.

The link between diabetes and changes in the amount of lipids such as LDL, HDL, and triglycerides in the body is contributing to the market growth. Thus, with the increasing number of patients who have diabetes, the demand for fibrate drugs will also augment over the forecast timeframe. For instance, according to the International Diabetes Federation (IDF), in India, adults who have diabetes were 774.2 Mn in 2021, with a prevalence rate of 8.3%. Furthermore, the constant focus of the market players on the development and launch of new and effective treatment options for cholesterol abnormalities will drive the growth of the fibrate drugs market in the upcoming years.

Fibrate Drugs Market Report Highlights

The fenofibrate segment is expected to witness significant growth, owing to the high efficacy of the drug in reducing triglyceride levels and LDL cholesterol.

The branded segment dominated the market, owing to the strong patent portfolio owned by various companies in the market.

The tablets segment accounted for the largest market share, owing to its longer shelf life and ability to accommodate higher active ingredient doses.

Hospital & retail pharmacy segment held the largest market share, owing to the increasing number of hospital admissions.

North America dominated the market, owing to the high burden of coronary heart disease and rising incidence of cholesterol abnormalities.

The market players include Viatris Inc., Aurobindo Pharma, Lupin Pharmaceuticals, Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals, Inc.

Polaris Market Research has segmented the fibrate drugs market report based on drug, product type, form, distribution channel, and region:

Fibrate Drugs, Drug Outlook (Revenue - USD Billion, 2019 - 2032)

  • Clofibrate
  • Gemfibrozil
  • Fenofibrate
  • Others

Fibrate Drugs, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Branded
  • Generic

Fibrate Drugs, Form Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsule
  • Tablet

Fibrate Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital & Retail Pharmacy
  • Online Pharmacy

Fibrate Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Fibrate Drugs Market Insights

  • 4.1. Fibrate Drugs - Industry Snapshot
  • 4.2. Fibrate Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High risk associated with the increased levels of low-density lipoproteins (LDL) will significantly drive the market growth
      • 4.2.1.2. The increasing prevalence of diabetes worldwide is expected to boost the demand for fibrate drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The availability of alternate treatment options is limiting the demand for fibrate drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Fibrate Drugs Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Fibrate Drugs Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
  • 5.3. Clofibrate
    • 5.3.1. Global Fibrate Drugs Market, by Clofibrate, by Region, 2019-2032 (USD Billion)
  • 5.4. Gemfibrozil
    • 5.4.1. Global Fibrate Drugs Market, by Gemfibrozil, by Region, 2019-2032 (USD Billion)
  • 5.5. Fenofibrate
    • 5.5.1. Global Fibrate Drugs Market, by Fenofibrate, by Region, 2019-2032 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Fibrate Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Fibrate Drugs Market, by Product Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
  • 6.3. Branded
    • 6.3.1. Global Fibrate Drugs Market, by Branded, by Region, 2019-2032 (USD Billion)
  • 6.4. Generic
    • 6.4.1. Global Fibrate Drugs Market, by Generic, by Region, 2019-2032 (USD Billion)

7. Global Fibrate Drugs Market, by Form

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • 7.3. Capsule
    • 7.3.1. Global Fibrate Drugs Market, by Capsule, by Region, 2019-2032 (USD Billion)
  • 7.4. Tablet
    • 7.4.1. Global Fibrate Drugs Market, by Tablet, by Region, 2019-2032 (USD Billion)

8. Global Fibrate Drugs Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Hospital & Retail Pharmacy
    • 8.3.1. Global Fibrate Drugs Market, by Hospital & Retail Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.4. Online Pharmacy
    • 8.4.1. Global Fibrate Drugs Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)

9. Global Fibrate Drugs Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Fibrate Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Fibrate Drugs Market - North America
    • 9.3.1. North America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
    • 9.3.2. North America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
    • 9.3.4. North America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.3.5. Fibrate Drugs Market - U.S.
      • 9.3.5.1. U.S.: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.3.6. Fibrate Drugs Market - Canada
      • 9.3.6.1. Canada: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • 9.4. Fibrate Drugs Market - Europe
    • 9.4.1. Europe: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.5. Fibrate Drugs Market - UK
      • 9.4.5.1. UK: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.6. Fibrate Drugs Market - France
      • 9.4.6.1. France: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.7. Fibrate Drugs Market - Germany
      • 9.4.7.1. Germany: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.8. Fibrate Drugs Market - Italy
      • 9.4.8.1. Italy: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.9. Fibrate Drugs Market - Spain
      • 9.4.9.1. Spain: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.10. Fibrate Drugs Market - Netherlands
      • 9.4.10.1. Netherlands: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.4.11. Fibrate Drugs Market - Russia
      • 9.4.11.1. Russia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • 9.5. Fibrate Drugs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.5. Fibrate Drugs Market - China
      • 9.5.5.1. China: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.6. Fibrate Drugs Market - India
      • 9.5.6.1. India: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.7. Fibrate Drugs Market - Japan
      • 9.5.7.1. Japan: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.8. Fibrate Drugs Market - Malaysia
      • 9.5.8.1. Malaysia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.9. Fibrate Drugs Market - Indonesia
      • 9.5.9.1. Indonesia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.5.10. Fibrate Drugs Market - South Korea
      • 9.5.10.1. South Korea: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • 9.6. Fibrate Drugs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.6.5. Fibrate Drugs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.6.6. Fibrate Drugs Market - South Africa
      • 9.6.6.1. South Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.6.7. Fibrate Drugs Market - Israel
      • 9.6.7.1. Israel: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.6.8. Fibrate Drugs Market - UAE
      • 9.6.8.1. UAE: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
  • 9.7. Fibrate Drugs Market - Latin America
    • 9.7.1. Latin America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.7.5. Fibrate Drugs Market - Mexico
      • 9.7.5.1. Mexico: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.7.6. Fibrate Drugs Market - Brazil
      • 9.7.6.1. Brazil: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
    • 9.7.7. Fibrate Drugs Market - Argentina
      • 9.7.7.1. Argentina: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AbbVie Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Ajanta Pharma Inc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. ANI Pharmaceuticals, Inc
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Aurobindo Pharma
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Cipla
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Lupin Pharmaceuticals, Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Sun Pharmaceutical Industries Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Viatris Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Zydus Group
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development